SCHEMBL4355817

SCHEMBL4355817

COc1ccc(Sc2ccccc2CNc2cc(Cl)c(C)c(Cl)c2O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.53
POLB P06746 2/20 0.53
MEN1 O00255 2/20 0.53
MMP2 P08253 5/20 0.47
MMP9 P14780 5/20 0.47
MMP12 P39900 5/20 0.47
MMP14 P50281 1/20 0.47
LMNA P02545 3/20 0.40
GAA P10253 3/20 0.40
KDM4E B2RXH2 2/20 0.36
MAPT P10636 2/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTT P42858 1/20 0.36
TP53 P04637 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
SLC6A4 P31645 2/20 0.35
SLC6A2 P23975 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4343949 0.89 SLC6A4 (0.45) KMT2APOLBMEN1LMNAGAA
SCHEMBL4345487 0.89 MAPT (0.39) KMT2APOLBMEN1LMNAGAA
SCHEMBL4346146 0.89 SMN1; SMN2 (0.41) KMT2APOLBMEN1GAAMAPT
SCHEMBL4359433 0.88 KMT2A (0.51) KMT2APOLBMEN1MMP2MMP9
SCHEMBL4349859 0.86 HTR1A (0.37) KMT2APOLBMEN1LMNAGAA
SCHEMBL4345485 0.85 KMT2A (0.55) KMT2APOLBMEN1MMP2MMP9
SCHEMBL4352978 0.84 POLB (0.58) KMT2APOLBMEN1MMP2MMP9
SCHEMBL4346931 0.83 PRMT1 (0.40) KMT2AMEN1GAAKDM4EMAPT
SCHEMBL4346467 0.83 SLC6A4 (0.49) KMT2APOLBMEN1LMNAGAA
SCHEMBL4349221 0.83 MAPT (0.46) KMT2AMEN1LMNAGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1539683-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS Jerini AG (DE) 2005-06-15 EP claimed
WO-2004030664-A2 NEW COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF JERINI AG (DE) 2004-04-15 WO claimed
WO-2004026815-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS JERINI AG (DE) 2004-04-01 WO claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 KMT2A 2096/4885POLB 3571/4885MEN1 2168/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 KMT2A 1254/4885POLB 2402/4885MEN1 3901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.